Summary
Insulin-like growth factor I (IGF I) is an endocrine hormone that mediates most of the effects of pituitary growth hormone. Other important regulatory factors of serum IGF I levels are insulin and nutrition. Most of the circulating IGF I is bound to three IGF binding proteins (BP), mostly IGFBP-3, BP-2 and BP-1. IGF I is also produced by many cells in the body where it exerts autocrine and/or paracrine effects. IGF I has a specific receptor on most cells, the so-called type 1 IGF receptor. When IGF I is administered intravenously as a bolus it leads to acute hypoglycaemia in a similar way to insulin and mainly with the insulin receptor. Chronic administration of IGF I to hypophysectomized or diabetic rats leads to prominent anabolic effects and growth. In this manuscript, metabolic and endocrine effects of recombinant IGF I are discussed. Recombinant IGF I therapy increases energy expenditure and lipid oxidation and decreases proteolysis and protein oxidation. These effects occur despite a partial inhibition of insulin and growth hormone secretion. The therapeutic spectrum of recombinant IGF I, consisting of inhibition of catabolism, stimulation of anabolism, decreases of triglyceride and cholesterol levels and a striking increase in insulin sensitivity, renders IGF I a very interesting, powerful tool for insulin-resistant states such as non-insulin-dependent diabetes mellitus.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- NIDDM:
-
Non-insulin-dependent diabetes mellitus
- IGF-I:
-
insulin-like growth factor-I
- IGFBP:
-
insulin-like growth factor binding protein
- rhIGF-I:
-
recombinant IGF I
References
Froesch, ER, Waldvogel M, Meyer UA, Jakob A, Labhart A (1967) Effects of 5-methylpyrazole-3-carboxylic acid on adipose tissue. II. Antilipolytic and hypoglycemic effects in vivo. Mol Pharmacol 3: 442–452
Froesch ER (1967) The physiology and pharmacology of adipose tissue lipolysis: its inhibition and implications for the treatment of diabetes. Diabetologia 3: 475–487
Froesch ER, Zapf J (1985) Insulin-like growth factors and insulin: comparative aspects. Diabetologia 28: 485–493
Schoenle E, Zapf J, Humbel RE, Froesch ER (1982) Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 296: 252–253
Scheiwiller E, Guler H-P, Merryweather J et al. (1986) Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 323: 169–171
Binz K, Zapf J, Froesch ER (1989) The role of insulin-like growth factor I in growth of diabetic rats. Acta Endocrinol (Copenh) 121: 628–632
Merimee TJ, Zapf J, Froesch ER (1982) Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 55: 999–1002
Schmid Ch, Ernst M, Binz K, Zapf J, Froesch ER (1991) The endocrine/paracrine actions of IGFs on bone. In: Spencer EM (ed) Modern concepts of insulin-like growth factors. Proceedings of the Second International Symposium on Insulin-Like Growth Factors/Somatomedins, January 12–16, 1991, San Francisco, California. Elsevier, New York, Amsterdam London Tokyo, pp 129–141
Guler HP, Zapf J, Froesch ER (1987) Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137–140
Zapf J, Schoenle E, Waldvogel M, Sand I, Froesch ER (1981) Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors. Further evidence for the action of insulinlike growth factors through the insulin receptor. Eur J Biochem 113: 605–609
Poggi C, Le Marchand-Brustel Y, Zapf J, Froesch ER, Freychet P (1979) Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology 105: 723–730
Schwander JC, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113: 297–305
Guler H-P, Zapf J, Schmid Chr, Froesch ER (1989) Insulinlike growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 121: 753–758
Bar RS, Clemmons DR, Boes M et al. (1990) Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart. Endocrinology 127: 1078–1086
Schmid Ch, Schläpfer I, Futo E et al. (1992) Triiodothyronine (T3) stimulates insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-2 production by rat osteoblasts in vitro. Acta Endocrinol (Copenh) 126: 467–473
Schmid Ch, Schläpfer I, Waldvogel M, Zapf J, Froesch ER (1992) Prostaglandin E2 stimulates synthesis of insulinlike growth factor binding protein-3 in rat bone cells in vitro. J Bone Miner Res 7: 1157–1163
Guler H-P, Schmid Ch, Zapf J, Froesch ER (1989) Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86: 2868–2872
Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER (1991) Recombinant human insulinlike growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 34: 675–679
Boulware SD, Tambourlane WV, Mathews LS, Sherwin RS (1992) Diurese effects of insulin-like growth factor I on glucose, lipid, and amino acids. Am J Physiol 262: E130-E133
Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W (1992) Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 75: 1186–1191
Jacob RE, Barrett E, Plewe G, Fagin KD, Sherwin RS (1989) Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 83: 1717–1723
Zenobi PD, Graf S, Ursprung H, Froesch ER (1992) Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 89: 1908–1913
Zenobi PD, Jaeggi-Groisman SE, Riesen W, Roder M, Froesch ER (1992) Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90: 2234–2241
Hussain MA, Schmitz O, Mengel A et al. (1993) Insulinlike growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in man. J Clin Invest 92: 2249–2256
Zenobi PD, Holzmann P, Glatz Y, Riesen WE, Froesch ER (1993) Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia 36: 465–469
Zenobi PD, Glatz Y, Keller A et al. (1994) Beneficial metabolic effects of insulin-like growth factor-I in patients with severe insulin resistant diabetes type A. Eur J Endocrinol, in press
Kuzuya H, Matsuura N, Sakamoto M et al. (1993) Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42: 696–705
Elliot S, Striker LJ, Peten EP, Conti FG, Striker GE (1993) The contribution of the growth hormone/insulin-like growth factor I axis to glomerulosclerosis. In: Flyvbjerg A, Orskov H, Alberti KGMM (eds) Growth hormone and insulin-like growth factor I in human and experimental diabetes. John Wiley & Sons Ltd, Chichester, pp 255–270
Hussain MA, Schmitz O, Mengel A et al. (1994) Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest, in press
Walker JL, Ginalska-Malinowska M, Rosner TE, Pucilowska JB, Underwood LE (1991) Effects of the infusion of insulin-like growth factor I in a child with growth hormoneinsensitivity syndrome (Laron dwarfism). N Engl J Med 324: 1483–1488
Guler H-P, Eckardt K-U, Zapf J, Bauer C, Froesch ER (1989) Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol (Copenh) 121: 101–106
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Froesch, E.R., Hussain, M. Recombinant human insulin-like growth factor-I: a therapeutic challenge for diabetes mellitus. Diabetologia 37 (Suppl 2), S179–S185 (1994). https://doi.org/10.1007/BF00400842
Issue Date:
DOI: https://doi.org/10.1007/BF00400842